Symbiotec Pharmalab LimitedSYMBIOTECCorporate

Drug Manufacturers - General Latest results: Jun 2026 1 quarters of data

₹1,198.00

MCap ₹7,519 Cr

Symbiotec Pharmalab Limited — Stock analysis & AI research Symbiotec Pharmalab Limited — Technical indicators & charts Symbiotec Pharmalab Limited — Live exchange announcements

AI-generated data: figures and text on this page are derived by AI agents from public quarterly filings and may contain errors or omissions — this website is managed by AI without human monitoring. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹211 Cr

Sales · Jun 2026

₹59 Cr

Operating Profit · Jun 2026

28.1%

OPM % · Jun 2026

₹47 Cr

Net Profit · Jun 2026

₹7.49

EPS · Jun 2026

📝 Symbiotec Pharmalab Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Symbiotec Pharmalab Limited reported revenue of ₹211 crore for the quarter ended June 2026 (Q1 FY27).

Net profit stood at ₹47 crore. Earnings per share (EPS) came in at ₹7.49.

Operating profit stood at ₹59 crore — an operating margin (OPM) of 28.1%.

Valuation snapshot

At the current price of ₹1,198.00, SYMBIOTEC has a market capitalisation of ₹7,519 crore.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹7,519 Cr

Current Price ?

₹1,198.0

P/E ?

N/A

Industry P/E ?

N/A

P/B ?

N/A

P/S ?

N/A

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹211 Cr

PAT — latest qtr ?

₹47 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

N/A

Debt to Equity ?

N/A

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

N/A

Change in promoter holding ?

N/A

Pledged percentage ?

N/A

Market

Return 3 months ?

9.1%

Return 6 months ?

9.1%

🗓️ Quarterly results (1 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Jun 2026	YoY %	QoQ %
Sales	211	—	—
Operating Profit	59	—	—
Other Income	20	—	—
Interest	6	—	—
Depreciation	10	—	—
Profit Before Tax	63	—	—
Net Profit	47	—	—
EPS	7.49	—	—
OPM %	28.1%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

⚖️ Peer comparison

Industry: Drug Manufacturers - General · 5 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	GLAXO GlaxoSmithKline Pharmaceuticals	₹2,818.90	47,754	44.7	3,955	1,068	40.8%	27.0%	1.9%	11.6%	16.6%	15.7%
2	RUBICON RUBICON RESEARCH	₹1,839.40	30,367	140.6	1,422	211	23.3%	14.9%	—	—	—	—
3	PFIZER Pfizer	₹4,055.00	18,551	25.7	2,519	723	35.9%	28.7%	10.4%	-5.8%	6.2%	-39.6%
4	SAIPARENT Sai Parenterals	₹523.95	2,315	165.1	473	14	9.6%	2.9%	—	—	—	—
5	SYMBIOTEC Symbiotec Pharmalab	₹1,039.00	—	—	—	—	—	—	—	—	—	—

❓ Frequently asked questions

What was Symbiotec Pharmalab Limited's revenue in Q1 FY27?

Symbiotec Pharmalab Limited reported revenue of ₹211 crore for the quarter ended June 2026 (Q1 FY27).

What was Symbiotec Pharmalab Limited's net profit in Q1 FY27?